# Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

> **NCT07053904** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **PharmaEssentia** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Sequential use of P1101 and P1801

## Key facts

- **NCT ID:** NCT07053904
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-21
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07053904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07053904, "Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07053904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*